🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASH24 just for context - in DETERMINATION published just a few years ago, MRD neg (10^-5) AFTER ASCT was ~54%. In MajesTEC-5, small n, but 100% MRD negativity BEFORE ASCT (after only 3 cycles)... + 1x-wkly V and #downwithdex! Amazing #MMsm data by Marc S. Raab Leo Rasche et al!

BCMA bispecifics: breaking the chains of resistance ow.ly/CBII50Uv0IP #immunobiologyandimmunotherapy

📣 #ESHMM2025 ONLY 4 DAYS LEFT TO SUBMIT YOUR ABSTRACT OR CLINICAL CASE Proceed now ➡ bit.ly/3THZibM 5th How to Diagnose & Treat MULTIPLE #MYELOMA 🗓️ Join us on April 3-5, 2025 in Vienna 🇦🇹 Chairs: Prof. Dr. Hermann Einsele, Maria Krauth, marivi mateos, Omar Nadeem #ESHCONFERENCES #MMsm

Now online in Cancer Discovery: Prenatal Exposure to Chemotherapy Increases the Mutation Burden in Human Neonatal Hematopoietic Stem Cells - by Ilana Struys, Carolina Velázque,z Joske Ubels, Liesbeth Lenaerts, Ruben van Boxtel, Frédéric Amant, et al. doi.org/10.1158/2159-8…

📣 We are excited to announce the 10th Heidelberg Myeloma Workshop   Join us on April 25–26, 2025, as international & local experts share the latest advancements in multiple myeloma research. #mmsm ✅ CME-certified 🔗 Speaker line-up & registration 👇🏼 myelomaworkshop.de

How does multiple myeloma progress? In our latest Science Immunology cover story, we reveal how myeloma cells breaking through bone trigger dangerous diversity. This arises from bidirectional interactions with the immune system, fueling disease evolution. scim.ag/4hMrLHs 1/2

Rahul Banerjee, MD, FACP Michael H. Tomasson, MD @MyelomaTeacher - Cindy Chmielewski MajesTEC-5 has a challenge-transplant arm with combo Tec/Tal replacing HDT/ASCT. Still a ph2 study with limited pt numbers but will get some data eventually. Leo Rasche #GMMG #DSMM Heidelberg Myeloma

Great to celebrate Dr Bart Barolgie chair of myeloma research investiture for Dr Zhan #mmsm and see Dr Barlogie and his family UAMS Myeloma Center with Dr Nikhil C. Munshi, MD who we enjoyed discussions with and certainly his talk about Dr Barolgie Congrats Frank , a well deserved honour

📢 MonumenTAL-1 Study Updates! Post-hoc analysis of talquetamab for relapsed/refractory multiple myeloma: 🔍ORR: 74%, 69% & 67% in the 0.4 mg/kg weekly, 0.8 mg/kg biweekly and previous TCR groups. 📈Grade 3–4 AEs: neutropenia, anemia & lymphopenia. 👇 tinyurl.com/2n6bcjnv

nature.com/articles/s4140… RW dosing patterns D0-2-4 SUD schedule was commonly used for Tec and Tal. Second SUD used in ~0.7% of cases. Long-term dosing- 1/3 of Tec doses after 3M were Q2W, and 13% were Q4W after 6M. Tal was mostly administered Q2W MCW Cancer Center #mmsm

🚨Did you know that nearly half of myeloma patients have clonal hematopoiesis during treatment? Find this and more in our new paper Blood Cancer Discovery Congrats Camila Guerrero Catarina Maia María José Calasanz CIMA LAB Diagnostics Clínica Universidad de Navarra Cima Universidad de Navarra PETHEMA! #mmsm aacrjournals.org/bloodcancerdis…

Myeloma Paper of the Day, April 24th, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center Meera Mohan oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #IVIG #MultipleMyeloma

We are delighted to share another insightful roundtable discussion from #iwMyeloma25 with you!🩸 Watch experts Faith E Davies, Leo Rasche & Arun Wiita discuss novel targets in #MultipleMyeloma and the role of the immune system in the disease: 👉 ow.ly/8h4950VG5vN #MMSM

iwMyeloma 2025 | VJHemOnc vjhemonc.com/event/iwmyelom…

Cilta-cel associated Parkinsonism remains a challenge. Instead of going right to high dose Cy which can be toxic to circulating CAR T cells, we opted to try intrathecal chemotherapy in 5 consecutive cases. 4/5 pts had a response and 3 complete resolution! IT chemo seemed to be

I think the timing of intervention is probably more important than the exact type when these MNTs develop after BCMA CAR-T in #MMsm… But jumping to high-dose Cy makes us nervous as Ben said, so good to see another effective option here! Now published in Blood Advances 👏

By ⁦nizar jacques bahlis⁩ at the ⁦COMy⁩ ⁦IACH⁩

1/ Another exciting year for myeloma #MMsm research! (IMROZ & BENEFIT last year seem like ages ago...) I'll miss #ASCO25 and #EHA2025 on paternity leave, but here are my top 10 #MMsm abstracts spanning CD38, BCMA, GPRC5D, and more... Thanks Mike Thompson, MD, PhD, FASCO as always for compiling!

#mmsm #ASCO25 Poster session-myeloma TALISMAN: Prophylactic Interventions for Oral Toxicities Talquetamab R/R MM ➡️phase II, 130 pts with different preventive measures to address oral toxicities Imp to see such studies done to address AEs and QoL, study schema and

Is there a difference in outcomes for patients receiving morning or evening chemoimmunotherapy infusion ? #ASCO25 we have the first randomized trial and its positive! Several retrospective studies showed that morning immunotherapy infusions are associated with longer survival.